NASDAQ:ARQT
Arcutis Biotherapeutics, Inc.
- Stock
Last Close
10.10
26/07 20:00
Market Cap
1.14B
Beta: 0.45
Volume Today
1.46M
Avg: 993.92K
PE Ratio
−1.36
PFCF: −2.77
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
net income | -4.98M - | -19.25M 286.80% | -42.00M 118.10% | -135.68M 223.07% | -206.36M 52.09% | -311.46M 50.93% | -262.14M 15.83% | |
depreciation and amortization | 195K - | 122K 37.44% | 454K 272.13% | 934K 105.73% | 1.88M 101.39% | |||
deferred income tax | 114K - | 3.45M 2,929.82% | 19.82M - | |||||
stock based compensation | 27K - | 151K 459.26% | 824K 445.70% | 7.94M 863.96% | 23.89M 200.79% | 32.68M 36.79% | 38.81M 18.76% | |
change in working capital | 279K - | 2.11M 655.56% | -1.50M 171.39% | 14.13M 1,039.07% | 3.62M 74.39% | -10.18M 381.08% | -23.50M 130.97% | |
accounts receivables | -8.46M - | -17.35M 105.12% | ||||||
inventory | -7.51M - | -5.62M 25.21% | ||||||
accounts payables | 537K - | 1.26M 135.38% | -458K 136.23% | 5.67M 1,338.86% | 245K 95.68% | 1.56M 538.78% | 3.15M 101.41% | |
other working capital | -258K - | 844K 427.13% | -1.05M 224.05% | 8.46M 907.93% | 3.38M 60.10% | 4.23M 25.39% | -3.68M 187.05% | |
other non cash items | 897K - | 2.91M 224.53% | -354K 112.16% | 333K 194.07% | 309K 7.21% | 30.30M 9,706.47% | -21.93M 172.36% | |
net cash provided by operating activities | -3.77M - | -14.09M 273.11% | -42.84M 204.12% | -113.03M 163.87% | -174.63M 54.49% | -257.71M 47.58% | -247.06M 4.14% | |
investments in property plant and equipment | -295K - | -321K 8.81% | -995K 209.97% | -23.28M 2,240% | -428K 98.16% | |||
acquisitions net | 26.03M - | 181.50M 597.28% | 74.96M 58.70% | 22.95M 69.38% | ||||
purchases of investments | -11.53M - | -60.83M 427.49% | -279.10M 358.82% | -292.51M 4.80% | -415.39M 42.01% | -225.84M 45.63% | ||
sales maturities of investments | 34.80M - | 97.60M 180.46% | 217.55M 122.90% | 351.47M 61.56% | 406.50M 15.66% | |||
other investing activites | -26.03M - | -181.50M 597.28% | -74.96M 58.70% | -22.95M 69.38% | ||||
net cash used for investing activites | -11.53M - | -26.32M 128.28% | -181.82M 590.69% | -75.95M 58.23% | -87.20M 14.81% | 180.23M 306.69% | ||
debt repayment | -72.35M - | -122.81M 69.75% | ||||||
common stock issued | 94.24M - | 297.00M 215.16% | 207.49M 30.14% | 176.05M 15.15% | 101.32M 42.45% | |||
common stock repurchased | 617K - | 842K 36.47% | 12.47M 1,380.76% | |||||
dividends paid | -72.35M - | -122.81M 69.75% | ||||||
other financing activites | 7.12M - | 61.59M 765.19% | -1.14M 101.84% | 526K 146.30% | 218.31M 41,404.75% | 358.91M 64.40% | ||
net cash used provided by financing activities | 7.12M - | 61.59M 765.19% | 93.10M 51.16% | 298.14M 220.23% | 281.95M 5.43% | 301.80M 7.04% | 101.32M 66.43% | |
effect of forex changes on cash | -50K - | |||||||
net change in cash | 3.34M - | 35.98M 975.84% | 23.94M 33.45% | 3.29M 86.27% | 31.37M 853.98% | -43.12M 237.46% | 34.45M 179.90% | |
cash at beginning of period | 74K - | 3.42M 4,518.92% | 39.39M 1,052.55% | 63.34M 60.78% | 66.62M 5.19% | 97.99M 47.08% | 54.88M 44.00% | |
cash at end of period | 3.42M - | 39.39M 1,052.55% | 63.34M 60.78% | 66.62M 5.19% | 97.99M 47.08% | 54.88M 44.00% | 89.32M 62.78% | |
operating cash flow | -3.77M - | -14.09M 273.11% | -42.84M 204.12% | -113.03M 163.87% | -174.63M 54.49% | -257.71M 47.58% | -247.06M 4.14% | |
capital expenditure | -295K - | -321K 8.81% | -995K 209.97% | -23.28M 2,240% | -428K 98.16% | |||
free cash flow | -3.77M - | -14.09M 273.11% | -43.13M 206.22% | -113.35M 162.81% | -175.62M 54.93% | -281.00M 60.00% | -247.49M 11.93% |
All numbers in USD (except ratios and percentages)